Cite
HARVARD Citation
Täubel, J. et al. (2018). Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments. Clinical pharmacology in drug development. 7 (8), pp. 889-900. [Online].